These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 16146157

  • 1. [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"].
    Shmueli D, Gross-Tsur V.
    Harefuah; 2005 Aug; 144(8):572-6, 597. PubMed ID: 16146157
    [Abstract] [Full Text] [Related]

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 3. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
    Bricard C, Boidein F.
    Encephale; 2001 Jun; 27(5):435-43. PubMed ID: 11760693
    [Abstract] [Full Text] [Related]

  • 4. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 5. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 6. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
    Heal DJ, Cheetham SC, Smith SL.
    Neuropharmacology; 2009 Dec; 57(7-8):608-18. PubMed ID: 19761781
    [Abstract] [Full Text] [Related]

  • 7. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 8. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
    Prince JB.
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
    [Abstract] [Full Text] [Related]

  • 9. New options in the pharmacological management of attention-deficit/hyperactivity disorder.
    Olfson M.
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S117-24. PubMed ID: 15352538
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B.
    Clin Neuropharmacol; 2009 Jul; 32(4):179-82. PubMed ID: 19644227
    [Abstract] [Full Text] [Related]

  • 11. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R, Hodgkins P, Meijer W.
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [Abstract] [Full Text] [Related]

  • 12. [Attention deficit hyperactivity disorder in adults: a clinical and therapeutic characterization].
    Ramos-Quiroga JA, Bosch-Munsó R, Castells-Cervelló X, Nogueira-Morais M, García-Gimenez E, Casas-Brugué M.
    Rev Neurol; 2010 Nov; 42(10):600-6. PubMed ID: 16703528
    [Abstract] [Full Text] [Related]

  • 13. Collicular dysfunction in attention deficit hyperactivity disorder.
    Overton PG.
    Med Hypotheses; 2008 Nov; 70(6):1121-7. PubMed ID: 18215471
    [Abstract] [Full Text] [Related]

  • 14. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P.
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [Abstract] [Full Text] [Related]

  • 15. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [Abstract] [Full Text] [Related]

  • 16. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA.
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [Abstract] [Full Text] [Related]

  • 17. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H.
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract] [Full Text] [Related]

  • 18. [Utilization of methylphenidate(Ritalin) in France].
    Frances C, Hoizey G, Millart H, Trenque T.
    Therapie; 2002 Sep; 57(2):189-93. PubMed ID: 12185970
    [Abstract] [Full Text] [Related]

  • 19. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 20. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D.
    Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.